1
1. Philit F, Etienne J, Calvet A, et al.
Infectious agents associated with exac-
erbations of chronic obstructive bron-
chopneumopathies and asthma attacks
al. Outbreaks of influenza A and B in a
highly immunized nursing home pop-
ulation. J Fam Pract 1997;45:509–514.
24. Murphy KR, Eivindson A, Pauksens
K, et al. Efficacy and safety of inhaled
zanamivir for the treatment of influ-
enza in patients with asthma or chronic
obstructive pulmonary disease: a dou-
ble-blind, randomised, placebo-con-
trolled, multicentre study. Clin Drug
Invest 2000;20:337–349.
25. Szilagyi PG, Rodewald LE, Savageau
J, et al. Improving influenza vaccina-
tion rates in children with asthma: a
test of a computerized reminder sys-
tem and an analysis of factors predict-
ing vaccination compliance. Pediatrics
1992;90:871–875.
26. Wiselka MJ, Kent J, Nicholson KG,
Stern M. Influenza and asthma. Lancet
1992;339:367–368.
27. Centers for Disease Control and Pre-
vention. Prevention and control of
influenza: recommendations of the ad-
visory committee on immunization
practices (ACIP). Morb Mortal Wkly
Rep 1999;48RR-4:1–28.
28. Aoki FY. Amantadine and rimanta-
dine. In: Nicholson KG, Webster RG,
Hay AJ, eds. Textbook of Influenza.
Oxford: Blackwell Science Ltd, 1998:
457–476.
29. Younkin SW, Betts RF, Roth FK,
Douglas RG Jr. Reduction in fever and
symptoms in young adults with influ-
enza A/Brazil/78 H1N1 infection after
treatment with aspirin or amantadine.
Antimicrob Agents Chemother 1983;
23:577–582.
30. Van Voris LP, Betts RF, Hayden FG,
et al. Successful treatment of naturally
occurring influenza A/USSR/77
H1N1. JAMA 1981;245:1128–1131.
31. Togo Y, Hornick RB, Felitti VJ, et al.
Evaluation of therapeutic efficacy of
amantadine in patients with naturally
occurring A2 influenza. JAMA 1970;
211:1149–1156.
32. Kitamoto O. Therapeutic effectiveness
of amantadine hydrochloride in influ-
enza A2–double blind studies. Jpn J
Tubercul Chest Dise 1968;15:17–26.
33. Hayden FG, Hay AJ. Emergence and
transmission of influenza A viruses re-
sistant to amantadine and rimantadine.
Curr Top Microbiol Immunol 1992;
176:119–130.
Resistance of influenza A virus to
amantadine and rimantadine: results of
one decade of surveillance. J Infect Dis
1989;159:430–435.
[in French]. Rev Mal Respir 1992;9:
36. Hayden FG, Gwaltney JM Jr, Van de
Castle RL, et al. Comparative toxicity
of amantadine hydrochloride and
rimantadine hydrochloride in healthy
adults. Antimicrob Agents Chemother
1
91–196.
1
1
1
2. Nicholson KG. Human influenza. In: Ni-
cholson KG, Webster RG, Hay AJ, edi-
tors. Textbook of Influenza. Oxford:
Blackwell Science Ltd, 1998:219–264.
3. Kondo S, Abe K. The effects of influ-
1
981;19:226–233.
3
7. Centers for Disease Control and Pre-
vention. Prevention and control of
influenza: recommendations of the ad-
visory committee on immunization
practices (ACIP). MMWR Morb Mor-
tal Wkly Rep 2000;49RR-3:1–38.
8. Woods JM, Bethell RC, Coates JA, et
al. 4-Guanidino-2,4-dideoxy-2,3-dehy-
dro-N-acetylneuraminic acid is a
highly effective inhibitor both of the
sialidase (neuraminidase) and of
growth of a wide range of influenza A
and B viruses in vitro. Antimicrob
Agents Chemother 1993;37:1473–1479.
9. Bardsley-Elliot A, Noble S. Oseltami-
vir. Drugs 1999;58:851–862.
40. Makela MJ, Pauksens K, Rostila T, et
al. Clinical efficacy and safety of the
orally inhaled neuraminidase inhibitor
zanamivir in the treatment of
influenza: a randomized, double-blind,
placebo-controlled European study.
J Infect 2000;40:42–48.
41. Hedrick JA, Barzilai A, Behre U, et al.
Zanamivir for treatment of symptom-
atic influenza A and B infection in
children five to twelve years of age: a
randomized controlled trial. Pediatr In-
fect Dis J 2000;19:410–417.
2. MIST (Management of Influenza in the
Southern Hemisphere Trialists) Study
Group. Randomised trial of efficacy and
safety of inhaled zanamivir in treatment
of influenza A and B virus infections.
Lancet 1998;352:1877–1881.
3. Nicholson KG, Aoki FY, Osterhaus
AD, et al. Efficacy and safety of osel-
tamivir in treatment of acute influenza:
a randomised controlled trial. Neur-
aminidase Inhibitor Flu Treatment In-
vestigator Group. Lancet. 2000;355:
enza virus infection on FEV in asth-
1
matic children. The time-course study.
Chest 1991;100:1235–1238.
4. Smith CB, Kanner RE, Golden CA, et
al. Effect of viral infections on pulmo-
nary function in patients with chronic
obstructive pulmonary diseases. J In-
fect Dis 1980;141:271–280.
5. Bohnen AM, Sand O, Griffin AD,
Keech ML. Impact of influenza/
influenza-like illness on patients with
asthma or COPD. Eur Respir J 1999;
3
1
1
1
4(Suppl):485.
6. Centers for Disease Control and Pre-
vention. Prevention and control of
influenza: recommendations of the ad-
visory committee on immunization
practices (ACIP). MMWR Morb Mor-
tal Wkly Rep 1997;46RR-9:1–25.
7. Fedson DS, Hirota Y, Shin HK, et al.
Influenza vaccination in 22 developed
countries: an update to 1995. Vaccine
3
1
1
1
997;15:1506–1511.
8. Nichol KL. Efficacy/clinical effective-
ness of inactivated influenza virus vac-
cines in adults. In: Nicholson KG,
Webster RG, Hay AJ, editors. Text-
book of Influenza. London: Blackwell
Science Ltd, 1998:358–372.
9. Gross PA, Hermogenes AW, Sacks
HS, et al. The efficacy of influenza
vaccine in elderly persons. A meta-
analysis and review of the literature.
Ann Intern Med 1995;123:518–527.
0. Bell TD, Chai H, Berlow B, Daniels G.
Immunization with killed influenza vi-
rus in children with chronic asthma.
Chest 1978;73:140–145.
1
4
2
2
4
1. Paul WS, Cowan J, Jackson GG. Acute
respiratory illness among immunized
and nonimmunized patients with high-
risk factors during a split season of
influenza A and B. J Infect Dis 1988;
1
845–1850.
4
4. Treanor JJ, Hayden FG, Vrooman PS,
et al. Efficacy and safety of the oral
neuraminidase inhibitor oseltamivir in
treating acute influenza: a randomized
controlled trial. US Oral Neuramini-
dase Study Group. JAMA 2000;283:
1016–1024.
1
57:633–639.
2
2
2. Sugaya N, Nerome K, Ishida M, et al.
Efficacy of inactivated vaccine in pre-
venting antigenically drifted influenza
type A and well-matched type B.
JAMA 1994;272:1122–1126.
34. Hayden FG. Amantadine and rimanta-
dine resistance in influenza A viruses.
Curr Op Infect Dis 1994;7:674–677.
35. Belshe RB, Burk B, Newman F, et al.
3. Drinka PJ, Gravenstein S, Krause P, et
VOLUME 87, DECEMBER, 2001
453